Infliximab therapy dampens immune response toCOVID-19 infection, research suggests
Pharmaceutical Journal
; 306(7948), 2022.
Article
in English
| EMBASE | ID: covidwho-2064946
antibody response; antiviral therapy; article; chronic infection; coronavirus disease 2019/dt [Drug Therapy]; health care policy; human; immune response; inflammatory bowel disease/dt [Drug Therapy]; recurrent infection; viral evolution; infliximab/cb [Drug Combination]; infliximab/dt [Drug Therapy]; mercaptopurine/cb [Drug Combination]; methotrexate/cb [Drug Combination]; vedolizumab/dt [Drug Therapy]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Pharmaceutical Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS